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Abstract Oxidative stress, and in particular oxidation of
lipoproteins, is a hallmark of atherosclerosis. Upon entry of
lipoproteins into the vessel wall, a cascade of pro-
atherogenic pathways is initiated whereby the reaction of
reactive oxygen species with substrates amenable to
oxidation, such as polyunsaturated fatty acids, generates a
variety of oxidation-specific epitopes on lipoproteins,
proteins in the vessel wall, and apoptotic macrophages.
Several of these oxidation-specific epitopes have been well
characterized and specific murine and fully human anti-
bodies have been generated in our laboratory to detect them
in the vessel wall. We have developed radionuclide,
gadolinium and iron oxide based MRI techniques to
noninvasively image oxidation-specific epitopes in athero-
sclerotic lesions. These approaches quantitate plaque
burden and also allow detection of atherosclerosis regres-
sion and plaque stabilization. In particular, gadolinium
micelles or lipid-coated ultrasmall superparamagnetic iron
oxide particles containing oxidation-specific antibodies
accumulate within macrophages in the artery wall, suggest-
ing they may image the most unstable plaques. Translation
of these approaches to humans may allow a sensitive
technique to image and monitor high-risk atherosclerotic
lesions and may guide optimal therapeutic interventions.
Keywords Atherosclerosis.Lipoproteins.Oxidation.
Antibody.Radionuclide imaging.Radioisotopes.Magnetic
resonance imaging
Introduction
Oxidative stress represents an imbalance between the
production and degradation of reactive oxygen species
(ROS), such as superoxide anion or hydrogen peroxide
created by myeloperoxidase, nitric oxide synthase, NADPH
oxidase, xanthine oxidase, and other oxidases [1￿, 2, 3￿].
Hyperlipidemia, inflammatory conditions, or endothelial
injury can cause increased ROS production, which can
modify fatty acids, lipoproteins, and amino acids, thereby
generating oxidation-specific epitopes (OSE). The charac-
terization of oxidation of low-density lipoprotein (OxLDL)
is a classic example of the consequences of a pro-oxidant
and proinflammatory environment, generating a variety of
OSE, such as the well-described oxidized phospholipid
(OxPL) and malondialdehyde (MDA) epitopes on LDL [4,
5]. These OSE are biologically active by upregulating
adhesion molecules to attract monocytes into the vessel
wall, can mediate proinflammatory responses in cytokines
and upregulation of pro-inflammatory genes, mediate
macrophage retention and apoptosis, and are cytotoxic.
OSE are pro-atherogenic by mediating the unregulated
uptake of OxLDL in macrophages through scavenger
receptors and generating activated macrophage foam cells.
Furthermore, OSE are potent immunogens and can activate
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DOI 10.1007/s12410-010-9060-6T cells and B cells, resulting in the generation of autoanti-
bodies directed to unique OSE that can be present on lipids
and proteins such as on OxLDL, lipoprotein (a) [Lp(a)],
within macrophage foam cells, on proteins in the extracel-
lular matrix, and on the surface of apoptotic cells [6￿￿].
It is now widely accepted that atherosclerosis is a
chronic inflammatory disease and does not simply result
from the bland accumulation of lipids [7]. The nature of the
inflammatory response includes the interaction of antigens,
such as OSE, and immune cells such as monocyte/macro-
phages, T cells, and B cells. OSE can be regarded as a
major target of many innate pattern recognition receptors,
which are preformed, germline-encoded receptors, and
presumably the product of natural selection. These OSE
Fig. 1 Oxidation-specific epitopes are a class of pathogen-associated
molecular patterns (PAMPs) that are recognized by natural antibodies
and other innate immune receptors. Physiological and pathological
stress can lead to the generation of oxidation-specific epitopes (altered
self) on membranes of lipoproteins as well as cells (self), which are
subsequently recognized by natural antibodies, scavenger receptors,
and other innate effector proteins via these motifs. In many, if not all,
cases, molecular mimicry exists between oxidation-specific epitopes
of self-antigens and epitopes of infectious pathogens. 4-HNE, 4-
hydroxynonenal; AGE, advanced glycation end product; CRP, C-
reactive protein; Lp(a), lipoprotein [a]; MDA, malondialdehyde;
OxCL, oxidized cardiolipin; OxLDL, oxidized LDL; PC, phosphor-
ylcholine; SAA, serum amyloid A. (Reprinted with permission from
Hartvigsen et al. [6￿￿])
Fig. 2 The left panel displays
an illustration of LDL that is
modified by a variety of
oxidation-specific epitopes,
including phosphocholine-
containing oxidized phospholi-
pids (oxPC), malondialdehyde
(MDA and 4-hydroxynonenal
[HNE] epitopes). The right
panel displays an illustration of
an IgG antibody showing its
various effector functions.
MDA2, E06, and IK17 are
well-characterized
oxidation-specific antibodies
Curr Cardiovasc Imaging Rep (2011) 4:4–16 5are ubiquitous in atherosclerotic lesions and represent
“danger signals,” thus constituting a class of pathogen-
associated molecular patterns, which have led to the natural
selection of multiple innate pattern recognition receptors
that target such epitopes. This includes both cellular pattern
recognition receptors, such as scavenger receptors and toll-
like receptors (TLRs) on macrophages, and soluble pattern
recognition receptors, such as natural antibodies. The
finding that natural antibodies secreted from OxLDL-
specific B-cell lines bind to oxidation-specific epitopes,
block uptake of OxLDL by macrophages, recognize
apoptotic cells, and are deposited in atherosclerotic lesions
suggested a new role of innate immunity and pathogen-
associated molecular patterns (Fig. 1)[ 6￿￿].
Taking advantage of the biological and immunological
properties of OSE, we have generated, characterized, and
evaluated murine and human monoclonal antibodies as
imaging agents. In this review, we will describe imaging of
atherosclerosis and macrophages using oxidation-specific
antibodies.
Antibodies to Oxidation-Specific Epitopes
MDA2
MDA2 is a murine monoclonal IgG type antibody specific
for MDA-lysine epitopes. It binds MDA-LDL, and other
Fig. 3 En-face preparations of Sudan-stained aortas from an apoE
−/−
mouse (a) and a Watanabe heritable hyperlipidemic (WHHL) rabbit
(b) injected with
125I-MDA2. Red color (left panels in a and b)
signifies the presence of neutral lipid within the atherosclerotic plaque
stained with Sudan IV, and black color (right panels in a and b) in the
corresponding autoradiograph signifies the presence of accumulated
125I-MDA2 reflecting the presence of MDA-lysine epitopes. Panel C
shows the relationship of
125I-MDA2 uptake and plaque burden as
measured by aortic weight. A similar relationship is present with
percent atherosclerosis surface area. Panels d and e represent in vivo
imaging of atherosclerotic WHHL (d) and nonatherosclerotic New
Zealand white (e) rabbits with
99mTc-MDA2. (Reprinted with
permission from Tsimikas et al. [9], [10￿])
6 Curr Cardiovasc Imaging Rep (2011) 4:4–16MDA-modified proteins, but not native LDL, high-density
lipoprotein, or very low-density lipoprotein [8]. MDA2
immunostains MDA-lysine epitopes in various stages of
atherosclerotic lesions, particularly early fatty streaks in
humans and intermediate lesions of mice and rabbits [9,
10￿, 11￿￿].
E06
E06 is a natural IgM autoantibody cloned from apolipo-
protein E–deficient mice (apoE
−/−) that binds to the
phosphocholine (PC) head group of oxidized but not
normal phospholipids [12]. E06 binds to PC of oxidized
phospholipids when it is exposed as a result of conforma-
tional changes induced by oxidative modification of
polyunsaturated fatty acid at the sn-2 position of phospho-
lipids. E06 blocks the uptake of OxLDL and apoptotic cells
by macrophages [13]. Interestingly, E06 is structurally and
functionally identical to classic “natural” murine T15 anti-
PC antibodies that are of B-1 cell origin and are reported to
provide optimal protection from virulent pneumococcal
infection [14]. This suggests that T15/E06 evolved through
natural selection from B-1 cells and their physiological role
may be in immune defense and housekeeping roles against
PC-containing organisms, clearance of PC-containing apo-
ptotic cells, and protection against oxidation-dependent
changes [6￿￿, 15].
IK17
IK17 is a human monoclonal IgG antibody fragment (used
either as a Fab fragment or single chain Fv fragment for
i m a g i n gp u r p o s e s )b i n d i n gt oM D A - L D La n dc o p p e r
OxLDL [16]. The exact chemical structure of the epitope
it recognizes is not fully defined, but it appears to be an
MDA-like epitope that is expressed during extensive
oxidative modification. IK17 was isolated from a phage
display library from a patient with coronary artery disease
with high plasma autoantibody titers to MDA-LDL. IK17
also inhibits the uptake of OxLDL and apoptotic cells by
macrophages. Because IK17 is a human autoantibody it has
potential advantages in imaging over murine antibodies to
OSE, including improved pharmacokinetics and reduced
immunologic reactions [16]. Figure 2 displays the concepts
of oxidation-specific epitopes as antigens and imaging
targets and oxidation-specific antibodies as the targeting
agents.
In a recent study in human vulnerable plaques, we
demonstrated that OSE were absent in normal coronary
arteries. Early lesions immunostained for all epitopes but
the overall extent was minimal. However, as lesions
progressed, the presence of apoB and MDA epitopes did
not increase, whereas OxPL and IK17 epitopes increased
Fig. 4 En face preparation of Sudan-stained mouse aortas (left)a n d
corresponding autoradiographs (right) showing representative examples
of intravenously injected
125I-MDA2 distribution in the progression (a)
and regression (b) groups. Arrowheads depict Sudan-stained areas with
diminished
125I-MDA2 uptake. Note that there is diminished 125I-
MDA2 uptake in areas of lipid stained plaques representing loss of
available MDA binding sites following regression. Panels c–j represent
examples of immunostained atherosclerotic lesions from LDLR
−/− mice
from the progression (c, e, g, i) and regression (d, f, h, j) groups.
Immunostaining was performed for OxLDL, macrophages, smooth
muscle cells (SMCs), and collagen. OxLDL and SMCs appear pink/
purple, macrophages black, and collagen bright blue. Scale bar=50 μm.
(Reprinted with permission from Torzewski et al. [11￿￿])
Curr Cardiovasc Imaging Rep (2011) 4:4–16 7proportionally, but to different extent, as plaques ad-
vanced and in parallel to macrophage immunostaining
[17]. OxPL and IK17 epitopes were strongest in late
lesions in macrophage-rich areas, lipid pools, and the
necrotic core. OxPL and IK17 epitopes were most
specifically associated with unstable and ruptured plaques.
Thus, human coronary atherosclerotic lesions manifest a
differential expression of oxidation-specific epitopes as
they progress. These data provide a scientific rationale for
targeting particular oxidation-specific epitopes for bio-
marker, imaging, and therapeutic (“biotheranostic”)a p p l i -
cations in humans.
Imaging Studies
Radionuclide Imaging
Initial studies aimed at imaging OSE were focused on using
radionuclide techniques in a variety of animal models,
Fig. 5 Schematic of S-acetyl
thioglycolic acid
N-hydroxysuccinimide ester
(SATA) attachment to
antibodies, micelle composition,
and attachment of antibodies to
micelles. a, Composition of the
micelles. b, Modification of the
antibodies with the SATA linker
to facilitate attachment to the
micelles via the maleimide
moiety. (Reprinted with
permission from Briley-Saebo
et al. [22￿￿])
Table 1 Physical and chemical properties and pharmacokinetics of Gd micelles
Formulation Size, nm r1, 60 MHz (s
−1mM
−1) Blood half-life, h %ID in liver of apoE
−/− mice at 24 h
apoE
−/− mice Wild-type mice
MDA2-micelles 22±2 9.3 14.3* 1.7 18±4
IK17-micelles 16±3 10.5 16.5* 1.8 18±4
E06-micelles 16±3 10.8 20.1* 1.7 32±2
IgG-micelles 16±4 10.4 1.4 1.3 18±3
Untargeted micelles 14±2 11.6 1.5 1.5 12±3
*P<0.001 compared to wild-type mice
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−/− and apoE
−/− mice, cholesterol-fed New
Zealand white rabbits, and Watanabe heritable hyperlipi-
demic (WHHL) rabbits using radiolabeled MDA2 and IK17
antibodies. In a series of experimental studies [9, 10￿, 11￿￿],
it was established that intravenously injected radiolabeled
antibodies strongly and preferentially accumulate within
lipid-rich, oxidation-rich atherosclerotic lesions, and partic-
ularly in areas of increased content of OSE in the
extracellular space or on foam cells as documented by
concurrent immunostaining. Autoradiography and Sudan-
stained images of aortas obtained 24 h after intravenous
injection of
125I-MDA2 into apoE
−/− mice and WHHL
rabbits revealed areas of lipid staining that were nearly
identical to the autoradiography signal generated by the
accumulation of
125I-MDA2 in the atherosclerotic lesions
(Fig. 3). The uptake of
125I-MDA2, evaluated as the percent
of the injected dose, was highest in the aorta compared to
all other organs and tissues examined. It was also
demonstrated that the uptake of
125I-MDA2 in atheroscle-
rotic lesions was proportional to the plaque burden
measured by both the percent atherosclerotic lesion area
and aortic weight [9, 10￿]. Interestingly, in the WHHL
rabbits, enhanced uptake of
125I-MDA2 was also noted in
the spleen and liver, which are known sites of the
accumulation of OxPL in humans with nonalcoholic
steatohepatitis (NASH), suggesting that it may be possible
to noninvasively image NASH with this approach [18].
Furthermore,
99mTc-MDA2 successfully noninvasively im-
aged lipid-rich, oxidation-rich plaques (Fig. 3). Similar
qualitative in vivo uptake and autoradiography results were
obtained with
125I-IK17 Fab in LDL
−/− mice, except for a
more rapid plasma clearance due to the smaller size of the
Fab fragment [16].
Imaging of the Progression and Regression
of Atherosclerosis
The ability to quantitatively image changes in any target in
atherosclerotic lesions, in this case OSE in the vessel wall,
would be an important feature of any noninvasive imaging
technique. This property would allow physicians to not
only detect disease but also to monitor disease longitudi-
Fig. 6 Representative
abdominal aorta (arrows)
enhancement in apoE
−/− mice as
a function of time following
injection of 0.075 mmol Gd/Kg
of micelles. The vessel to the left
of the aorta is the inferior vena
cava (IVC). The bright white
areas at the abdominal aorta
represent magnetic resonance
enhancement of atherosclerotic
plaque due to accumulation of
antibody-tagged Gd micelles.
Although arterial flow was sat-
urated to allow for delineation of
the arterial wall, some enhance-
ment in the IVC may be
observed due to flow artifacts.
(Reprinted with permission from
Briley-Saebo et al. [22￿￿])
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other therapeutic interventions. We have successfully
established that, in principle, oxidation-specific antibodies
can perform this type of function. In a dietary regression
study, LDLR
−/− mice were fed a high-cholesterol, high-fat
diet for 6 months and either continued on this diet
(progression group) or placed back on normal mouse chow
(regression group) for an additional 6 months, and each
group was then injected with
125I-MDA2. Uptake of
125I-
MDA2 was markedly reduced in mouse lesions undergoing
atherosclerosis regression and correlated very strongly with
features of plaque stabilization, including reduced macro-
phage content and increased collagen and smooth muscle
cell content (Fig. 4)[ 10￿, 11￿￿]. In addition, in this study
and another rabbit study, there was evidence obtained by
immunostaining that OSE disappeared from the vessel wall
following a low-fat diet prior to physical plaque regression,
suggesting that this may be a very early mechanism of
plaque stabilization [19, 20].
These data in atherosclerotic mouse models are consis-
tent with human data on the composition change of human
carotid plaques following treatment with pravastatin for
3 months, where immunocytochemical staining by NA59,
an antibody binding to the OSE 4-hydroxynonenal (HNE),
and its quantitative analysis revealed significantly less
immunoreactivity for HNE epitopes in the pravastatin-
treated group compared to the control group [21]. These
data suggest that both dietary and statin-induced lipid-
lowering therapy are associated with changes in human
carotid plaque composition that favor lesion stability and
that these changes can be detected and imaged with
oxidation-specific antibodies.
MRI Using Gadolinium Micelles Containing
Oxidation-Specific Antibodies
One of the limitations discovered in using radionuclide
techniques with this approach was the modest target-to-
blood ratios, which were not mediated by diminished
plaque uptake of the
125Io r
99mTc radiolabeled antibodies,
but instead by the high blood background due to the slow
clearance of the radiolabeled antibodies. For translation to
clinical imaging, because of the relatively short radiolabel
half-life of
99mTc and the relatively long biological half-life
of antibody clearance, an optimal window where the
maximal antibody uptake and binding coinciding with the
maximal photon flux of
99mTc was not feasible. This
resulted in
99mTc images that were suboptimal for a
quantitative assessment of OSE. Thus far, PET techniques
have not been evaluated with this approach.
To overcome this challenge, a series of experiments were
performed using an MRI approach where oxidation-specific
antibodies were covalently attached to gadolinium (Gd)-
containing micelles (~50 gadolinium ions per micelle)
[22￿￿]. In short, micelles were prepared using 1,2-dis-
tearoyl-sn-glycer-3-phosphoethanolamine-n-methoxy (poly-
Fig. 7 Confocal microscopy
(63×) of apoE
−/− mouse aortic
atherosclerotic plaque following
the administration of MDA2-
micelles and E06-micelles dem-
onstrating nuclei (blue), macro-
phages (green), and micelles
(red). The lower panels repre-
sent an atherosclerotic plaque
from an apoE
−/− mouse not
injected with micelles and
stained with DAPI, showing the
absence of significant autofluor-
escence (40×). (Reprinted with
permission from Briley-Saebo et
al. [22￿￿])
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DSPE by dissolving in chloroform:methanol with rhodamine
added as a fluorescent label (Fig. 5). MDA2-micelles, E06-
micelles, and IK17-micelles were modified with S-
acetylthioglycolic acid N-hydroxysuccinimide ester and then
covalently linked to the surface of the gadolinium micelles.
The hydrated diameter of the micelles was 14 to 22 nm and
their r1 values at 60 MHz were approximately 10 s
−1 *
mmol/L
−1 (Table 1).
MRI was performed at 9.4 Tesla over a 96-hour time
interval after the administration of 0.075 mmol Gd/kg
micelles. MDA2-micelles and IK17-micelles showed
maximal arterial wall uptake at 72 h and E06-micelles
at 96 h, manifested by 125% to 231% enhancement in
MR signal compared to adjacent muscle in cholesterol-
fed apoE
−/− mice. In vivo imaging revealed significant
signal enhancement with all targeted micelles, compared
to untargeted micelles or micelles tagged with a nonspe-
cific antibody (Fig. 6). No significant enhancement was
Fig. 8 Confocal microscopy (63×) showing the association of
micelles with macrophages in in vitro experiments. Macrophages
and micelles were either exposed (+) or not exposed (–) to MDA-LDL
prior to mixing together in cell culture. Red (rhodamine) represents the
presence of micelles and blue (DAPI) macrophage nuclei. The
numbers under each panel represent gadolinium content measured
by inductively coupled plasma mass spectrometry (ICP-MS) normal-
ized to total cell number. (Reprinted with permission from Briley-
Saebo et al. [22￿￿])
Fig. 9 Schematic diagram of the lipid-coated iron oxide particles. The
lipid-coated LUSPIOs were prepared by first synthesizing the mono-
crystalline and mono-disperse iron core. PEG-DSPE, PEG-malamide-
DSPE,andlissrhodamineareaddedataratioof17.3mg:1.3mg:0.12mg
per milligram iron. Antibodies (0.35 mg/mg Fe) were attached to the
LUSPIO and LSPIO surface via S-acetyl thioglycolic acid N-
hydroxysuccinimideester modification.(Reprinted with permission from
Briley-Saebo et al. [28￿￿])
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or IgG micelles or of any micelles in wild-type mice.
When excess free MDA2 was pre-injected, the plaque
enhancement of MDA2 micelles was significantly reduced
to a level comparable to that of untargeted micelles,
confirming a specific targeting mechanism. Confocal
microscopy confirmed the association of the MDA2
micelles and E06 micelles within the arterial vessel wall
of apoE
−/− mice and colocalization of rhodamine of
micelles with markers of macrophages showing uptake
of micelles by macrophages (Fig. 7).
The uptake of targeted micelles within macrophages
suggested the possibility of extracellular interactions of
OxLDL with the targeted micelles. To ascertain this, we
incubated macrophages that were pre-exposed to MDA-
LDL with MDA2-micellles that were also pre-incubated
with MDA-LDL and measured uptake by macrophages by
confocal microscopy and quantitatively by ICP-MS studies
(Fig. 8). The qualitative results indicate that when micelles
were pre-exposed to MDA-LDL there was limited associ-
ation of micelles with macrophages (column 1). When the
macrophages were pre-exposed to MDA-LDL but the
micelles were not there was association of MDA2-
micelles and IK17-micelles with macrophages (column 2).
When the MDA2-micelles and IK17-micelles were pre-
incubated with MDA-LDL but the macrophages were not,
there was even greater association of MDA2-micelles and
IK17-micelles with macrophages (column 3). Finally, when
both macrophages and micelles were pre-exposed to MDA-
LDL, the highest association of MDA2-micelles and IK17-
micelles with macrophages was noted (column 4). In
contrast, minimal association of IgG-micelles or untargeted
micelles was noted in any condition. This strongly suggests
the mechanism that the entry of micelles within macro-
phage occurs on activated macrophages when the antibody-
micelles interact with extracellular OxLDL and the entire
particle is taken up within the macrophage. Studies are
underway to assess the role of macrophage scavenger
receptors or other uptake pathways, such as macropinocy-
tosis, in the uptake of these targeted micelles.
MRI Using Iron Oxide Particles
One disadvantage of using gadolinium-based MRI contrast
agents is the potential for nephrogenic systemic fibrosis in
renally impaired patients following injection of clinically
available low-molecular-weight Gd chelates [23]. Gd is
known to come off its chelate at low (2%–3%) but
measurable rates, and free Gd can be toxic to cells and
induce apoptosis [24]. Gd also has lower relaxivity
compared to iron oxide nanoparticles. To circumvent this
issue, we have recently explored the use of biocompatible
iron oxide nanoparticles containing oxidation-specific anti-
bodies to target them to atherosclerotic lesions, and
specifically to macrophages. Prior studies with dextran-
coated ultrasmall iron oxide particles (USPIOs) have
passively targeted intraplaque macrophages [25]. These
USPIOs are desirable from a safety point of view, since
cells associated with the reticuloendothelial system are able
to safely eliminate iron [26]. However, this passive
targeting strategy may be suboptimal since these materials
require slow infusion and long time-intervals between
administration and MRI (>24 h) [27].
We therefore hypothesizedthatpegylated,lipid-coatediron
oxideparticles(withoutdextran)targetedtooxidation-specific
epitopes may increase the clinical utility of the iron oxide
platformforMRIofvulnerable atheroscleroticplaques.Lipid-
coated ultra-small superparamagnetic iron particles (LUSPIO,
<20 nm) and superparamagnetic iron particles (LSPIO,
<40 nm) were conjugated with antibodies targeted to either
MDA-lysine or oxidized phospholipid epitopes (Fig. 9). All
formulations were characterized and their in vivo efficacy
Table 2 Physical and chemical properties of lipid-coated ultra-small superparamagnetic iron particles (LUSPIO) and superparamagnetic iron
particles (LSPIO)
Formulation Size, nm r1, s
−1mM
−1 r2, s
−1mM
−1 Blood half-life
apoE
−/−, h
Blood half-life
WT, h
%ID in liver (24 hrs p.i)
Untargeted LUSPIO 10±3 14±1 35±2 1.52 1.41 25
Untargeted LSPIO 35±5 12±1 103±4 1.02 1.01 35
MDA2 LUSPIO 14±3 13±1 37±2 9.01 1.55 31
MDA2 LSPIO 38±4 11±1 117±5 7.28 1.12 37
IK17 LUSPIO 12±2 14±1 35±2 9.12 31
IK17 LSPIO 36±4 10±1 106±5 7.30 34
E06 LUSPIO 16±4 12±1 38±2 9.32 30
E06 LSPIO 39±5 11±1 119±6 7.42 35
All sizes are based upon the weighted number averages. The relaxivities shown were obtained in buffer at 60 MHz and 40°C. All blood half-lives
and percent injected dose (%ID) in the liver were obtained in apoE
−/− or wild-type (WT) mice after injection of a 3.9-mg Fe/Kg dose
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−/− mice 24 h after bolus administration of
a 3.9 mg Fe/kg dose using MRI (Table 2)[ 28￿￿].
All MRI was performed at 9.4 Tesla using an 89-mm
bore system operating at a proton frequency of 400 MHz
(Bruker Instruments, Billerica, MA) prior to and 24 hours
after the administration of a 3.9-mg Fe/Kg dose. In order to
obtain in vivo R2* maps, multiple echo GRE sequences
with the following pulse sequence parameters were applied:
TR=29.1 ms, TE=5.1 ms to 10 ms (n=5), flip angle=30°,
number of signal averages (NEX)=6, in-plane resolution=
0.098 mm
2, and 100% z-rephasing gradient. Twenty slices
were acquired from the level of the renal arteries to the iliac
bifurcation. R2*-maps were generated for matched pre and
post images on a pixel-by-pixel basis using a custom
Matlab program (The Mathworks, R2007b). The signal
intensity associated with each pixel was normalized to the
standard deviation of adjacent noise (placed above the spine
of the mouse) prior to linear fitting of the signal-to-noise
ratio versus echo time (TE). R2* values were then obtained
using regions of interest drawn on the arterial wall on slices
Fig. 10 Representative in vivo
LUSPIO MRIs obtained prior to
(pre) and 24 h after administra-
tion of a 3.9-mg Fe/Kg dose in
apoE
−/− mice. The yellow
arrows indicate the position of
the lumen associated with the
abdominal aorta. All GRE
images shown were obtained
using an echo time of 7 ms.
Corresponding white marker
GRASP images are also shown.
For the competitive inhibition
results, apoE
−/− mice were ad-
ministered free excess MDA2
antibody at the time of MDA2-
labeled LUSPIO injection.
Matched histology sections
show iron deposition (blue)
within foam cells associated
with the arterial wall. Relative
percent changes in the R2*
values associated with the arte-
rial wall following administra-
tion of the LUSPIO
formulations are also shown
(bottom panel). The error bars
reflect the standard deviation
associated with mean value
obtained for mice receiving
untargeted LUSPIOs and n=6
mice receiving MDA2 or E06-
labeled LUSPIOs. (Reprinted
with permission from Briley-
Saebo et al. [28￿￿])
Curr Cardiovasc Imaging Rep (2011) 4:4–16 13Fig. 11 Immunohistochemistry (top panel) and confocal microscopy
(bottom panel) of MDA2-labeled LUSPIOs in the arterial wall of
apoE
−/− and wild-type mice. The arterial wall was stained for MDA-
lysine (MDA3 staining), macrophages (MAC3), and iron oxide
(Perl’s) deposition. Confocal microscopy was using a multichannel
laser so that co-localization between the cell nuclei (blue), macro-
phages (green), and MDA2-labeled LUSPIOs (red) could be
performed. (Reprinted with permission from Briley-Saebo et al. [28￿￿])
14 Curr Cardiovasc Imaging Rep (2011) 4:4–16(n>5) exhibiting either R2* modulation post contrast or
arterial wall thickening, indicative of plaque deposition.
The relative percent changes in the R2* values were
determined as% change=((R2*post-R2*pre)/R2*post)*100.
Immediately following GRE acquisition, a GRASP
sequence was applied using 50% of the z-rephasing
gradient. GRASP is extremely useful when trying to
determine if MR signal loss is due to iron oxide deposition
or other endogenous artifacts (motion, partial voluming,
and perivascular effects) that may also promote signal loss.
GRASP cannot be used alone, however, since this sequence
does not provide adequate anatomic information. In
similarity to GRE sequences, GRASP signal may be
observed in lymphatic tissue that may also sequester the
iron oxide particles. However, this sequence is extremely
useful to differentiate between iron oxide deposition and
artifacts that are often present when imaging the arterial
wall. Blooming artifacts cause the GRE images to some-
times show uniform signal loss while the GRASP images
show focal, nonuniform enhancement. Phantom studies
have indicated that GRASP sequence is less susceptible to
blooming artifacts since very localized field inhomogene-
ities are required to produce strong GRASP signal. If the
iron oxide particles are uniformly distributed or if the field
distribution is large, then the GRASP signal is reduced
since the local susceptibility differences cannot be matched.
In vivo imaging data were correlated with the presence
of oxidation-specific epitopes using immunohistochemistry.
MRI of atherosclerotic lesions, as manifested by signal loss,
was observed following administration of targeted LUS-
PIOs (Fig. 10). In vivo competitive inhibition studies
showed a 74.9% (P=0.0002) reduction in R2* for mice
administered free MDA2 at the time of MDA2-labeled
LUSPIO micelle injection, again implying a specific
targeting mechanism. Limited signal attenuation was
observed for untargeted LUSPIOs. Additionally, no signif-
icant arterial wall uptake was observed for targeted or
untargeted LSPIOs due to their limited ability to penetrate
the vessel wall. Immunohistochemistry of aortas of apoE
−/−
mice administered the MDA2-labeled LUSPIO showed
strong correlation between iron oxide (Perls’ staining) and
MDA-lysine epitope deposition (Fig. 11). Limited LUSPIO
and MDA-lysine was observed in age-matched wild-type
mice. Additionally, confocal microscopy confirmed the
uptake of the oxidation-specific targeted LUSPIOs (rhoda-
mine labeled) within atherosclerotic lesions and specifically
within intraplaque macrophages/foam cells (anti-CD68
labeled) 24 hours post-injection. Rhodamine-labeled tar-
geted LUSPIOs were not observed in the extracellular
matrix. These results are consistent with the findings
reported for MDA2-Gd micelles [22￿￿]. Additionally, strong
co-localization between MDA epitopes and Perls’ Prussian
blue staining was observed, thereby confirming the pres-
ence of the targeted LUSPIOs in macrophages/foam cells
enriched in oxidation-specific epitopes.
These pegylated nanoparticles do not appear to be
selectively taken up by macrophages unless they also contain
an oxidation-specific antibody. In this way, they appear to
selectivelyaccumulateprimarilywithinlipid-richmacrophage
foam cells, perhaps due to binding extracellular OxLDL at
these sites or to OxLDL bound on macrophage scavenger
receptors that mediate particle uptake.
Conclusions
These sets of studies demonstrate that it is feasible to
noninvasively image and quantitate oxidation-specific epito-
pes associatedwithatherosclerosis withbothradionuclideand
MRI techniques, particularly with biocompatible iron oxide
nanoparticles that specifically target macrophages. The OSE
targets are biologically validated as being strong markers of
thepresenceandprogressionofatherosclerosis.Theantibody-
targeting agents appear to not only detect plaque burden, but
importantly plaque composition, particularly plaque enriched
in oxidized lipids and activated macrophages. Future studies
will focus on translating these observations to human
applications using human antibody fragments, such as single
chain IK17, which have particular appeal for detecting
advanced OSE in human vulnerable and ruptured plaques.
The ability to detect and quantify OSE in humans will allow
detection of high-risk plaques and provide the tools to allow
surveillance following a variety of therapeutic interventions.
This approach will have particular appeal initially in the
carotid and peripheral circulation and, with advances in
imaging techniques, possibly in coronary arteries as well.
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